(Reuters) – The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix Inc’s treatment for seizures associated with Dravet syndrome, a rare form of childhood epilepsy, the company said. As part of a preliminary review, FDA determined that the application was not sufficient enough for a substantive review. …Continue reading article
Since 1850, we have experimented, invented, and created content and news solutions to become the world’s leading international news agency. Always at the forefront of real-time breaking news and high-impact global multimedia content, we are constantly innovating our products and services to meet your business needs. Whether we are serving broadcasters, publishers, brands, agencies, or direct to consumers, Reuters provides award-winning coverage of the day’s most important topics, including: business, finance, politics, sports, entertainment, technology, health, environment, and much more.